inVentiv Health in $1.1 billion sale to private equity firm

Share this article:
InVentiv Health is being acquired by Thomas H. Lee Partners for $1.1 billion.

As MM&M went to press, stockholders were set to vote on the planned sale, announced in May, to Papillon Holdings, Inc., a Thomas H. Lee subsidiary, at a July 21 meeting. Shares in the company had jumped past $25 in anticipation of a sale.

InVentiv Health formed from the 2005 merger of a private agency network, Columbus-based InChord Communications, and Ventiv Health, a Somerset, NJ-based, publicly-held contract sales firm, for $185 million. At that time, the InChord agencies, including GSW Worldwide and Palio Communications, were expected to contribute a quarter of the combined company's revenue. By the end of 2009, it was closer to a third, with the communications division contributing $310 million in revenues.

InVentiv saw its revenues fall from $1.12 billion in 2008 to $1.07 billion in 2009, but the company said that the sour economy and the contracting US pharma industry did not prompt the move.

“There are several reasons we decided to enter into this transaction,” said Marcia Frederick, head of PR at InVentiv. “Going private will enable InVentiv to take a longer-term approach to gr

owth, rather than focusing so intently on quarter-over-quarter performance. It also will allow us to make strategic investments that will help us to continue expanding our offerings to clients. Finally, we selected THL because they understand and support our corporate vision, bring strong strategic insights, and are committed to working with us to achieve long-term growth.”

The company faces an investor lawsuit, filed in Delaware State Court, alleging breaches of fiduciary duty by the board of the company, which the litigants allege sold too cheaply. At press time, the complaint had not yet been certified by a judge, making it unclear whether the case could go forward.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete October 2014 Digital Edition

Read the complete October 2014 Digital Edition

Click the above link to access the complete Digital Edition of the October 2014 issue of MM&M, with all text, charts and pictures.

Predicting your pink slip

Predicting your pink slip

Any time a firm needs to save money, high-salaried executives are targets

Private View: New ways to engage with customers

Private View: New ways to engage with customers

These healthcare social media campaigns successfully use emotion, altruism and the human desire to "brand" oneself to get customers engaged.